![](https://news.europawire.eu/wp-content/uploads/2023/03/OncoC4-licenses-next-generation-anti-CTLA-4-monoclonal-antibody-candidate-to-BioNTech-144x144.jpg)
(IN BRIEF) BioNTech and Duality Biologics have announced the commencement of a pivotal Phase 3 trial for BNT323/DB-1303, a next-generation antibody-drug conjugate (ADC) targeting the Human Epidermal Growth Factor Receptor 2 (HER2) in metastatic breast cancer. The trial will enroll … Read the full press release